Patents Assigned to The United States of America as represented by the Department of Health, Education and Welfare
  • Patent number: 4183360
    Abstract: A photoplethysmographic instrument for simultaneous recordings of multifinger blood flow. The instrument consists of a plurality of suitably spaced and angled finger-receiving housings, each containing a photodetector, with respective light pipe bundles conducting light from a common source to the housings. The photodetectors respond to differences in light transmission through the patient's fingers inserted in the housings. The photodetectors are connected through respective preamplifiers to the respective inputs of a multichannel recorder, thereby providing recorded traces of the respective optical transmissions through the fingers. The photodetectors may also be connected to the respective inputs of a multichannel tape recorder, thereby providing magnetic tape recordings of the respective optical transmissions.
    Type: Grant
    Filed: July 26, 1978
    Date of Patent: January 15, 1980
    Assignee: The United States of America as represented by the Department of Health, Education and Welfare
    Inventors: Walter Carlson, Donald Wasserman, William Asburry
  • Patent number: 4183864
    Abstract: Steroid compounds obtained by co-oligomerization of a side chain functionalized 1,5-hexadiyne with bis(trimethylsilyl)acetylene catalyzed by cyclopentadiene cobalt dicarbonyl, CpCO(CO).sub.2, via intermediate benzocyclobutene formation followed by intramolecular cycloaddition to the sterospecific formation of the steroid nucleus. This constitutes a short steroid synthesis, five steps from commercially available acyclic precursor 1,5-hexadiyne and three steps from 2-methyl-cyclopent-2-enone.
    Type: Grant
    Filed: February 21, 1978
    Date of Patent: January 15, 1980
    Assignee: The United States of America as represented by the Department of Health, Education and Welfare
    Inventors: K. Peter C. Vollhardt, Raymond L. Funk
  • Patent number: 4169011
    Abstract: 3'-Phosphoadenosine 5'-phosphosulfate, also known as PAPS, is useful in establishing sulfate transfer mechanisms in animals and may be produced by a chemical process yielding 68-72% product from a pure adenosine 2',3'-cyclic phosphate 5'-phosphate, which compound is initially prepared from the reaction of adenosine and pyrophosphoryl chloride. In the present procedure the pure cyclic phosphate is reacted with triethylamine-N-sulfonic acid to produce 2',3'-cyclic phosphate 5'-phosphosulfate. Subsequently, by hydrolysis with the enzyme ribonuclease-T.sub.2, the desired compound is produced. Alternatively, the 2'-phosphoadenosine 5'-phosphosulfate, known as iso-PAPS, may be produced from 2',3'-cyclic phosphate 5'-phosphosulfate by treatment with a different enzyme, PDase or spleen phosphodiesterase. This latter compound, iso-PAPS, biologically has only one-third the activity of PAPS, the natural isomer.
    Type: Grant
    Filed: October 11, 1977
    Date of Patent: September 25, 1979
    Assignee: The United States of America as represented by the Department of Health, Education and Welfare
    Inventors: Jerome P. Horwitz, John P. Neenan, Radhey S. Misra, Jurij Rozhin, Anne L. Huo, Kirsten D. Philips, deceased
  • Patent number: 4167633
    Abstract: An improved process for the production of ##STR1## FROM ##STR2## WHICH PRODUCES BUT DOES NOT ISOLATE AN INTERMEDIATE ##STR3## WHICH COMPOUND IS RETAINED IN SITU AND MINIMIZES THE COMPLEX POLYMER FORM OF A THREE-DIMENSIONAL NETWORK OF AZO LINKAGES FORMED BY THE NITROSO AND AMINO GROUPS. These groups, as they appear in the nitroso intermediate, have carcinogenic possibilities. It has been found that the nitroso compound will precipitate as a stirrable slurry if the temperature parameter is kept low at about 0.degree.-20.degree. C. A preferred route for the production of the nitroso compound from the triamino starting material utilizes as reactants 1.0-1.05 moles of sodium nitrite and 1.5 moles of HOAc in water (HCl may be substituted for HOAc). In the second state of this sequential reaction, the reduction of nitroso is carried out by a reducing agent and one preferred agent is sodium dithionite. Catalytic agents such as Raney nickel and hydrazine or nickel salts, e.g.
    Type: Grant
    Filed: July 20, 1977
    Date of Patent: September 11, 1979
    Assignee: The United States of America as represented by the Department of Health, Education and Welfare
    Inventor: Thomas J. Morrow
  • Patent number: 4165182
    Abstract: A method and apparatus for directly obtaining displacement-amplitude information from a quadrature-dual interferometer. The system uses a "mini-wiggler" to introduce phase shift into the reference beam, as by oscillating a reference mirror with a piezo-electric crystal. The mini-wiggler produces relatively small phase perturbations of the order of 0.001.lambda. at a frequency at either edge or in the middle of the signal frequency band. The system uses a signal-processing circuit to obtain displacement amplitude directly. The purpose of the mini-wiggler is to produce a "pilot" signal of known amplitude and phase from which the correction terms needed to compensate for variations in the interferometer state, such as those caused by vibration, large variation, drift, and the like, are derived and can be applied by means of another signal processing circuit.
    Type: Grant
    Filed: December 9, 1977
    Date of Patent: August 21, 1979
    Assignee: The United States of America as represented by the Department of Health, Education and Welfare
    Inventor: David H. R. Vilkomerson
  • Patent number: 4162761
    Abstract: A flow-through coil planet centrifuge has variable rotation-revolution (r/R) speed ratios. The rotation and revolution are continuously adjustable by using separate variable-speed drive motors. A first embodiment employs rotating seals, whereas a second embodiment is without rotating seals. In the rotating seal embodiment the flow tubes are rotated synchronously with the column to avoid twisting; in the non-rotating seal embodiment a system of gearing and belts compensates for the rotation and revolution of the column relative to a stationary tube support to avoid twisting of the flow tubes.
    Type: Grant
    Filed: November 30, 1977
    Date of Patent: July 31, 1979
    Assignee: The United States of America as represented by the Department of Health, Education and Welfare
    Inventor: Yoichiro Ito
  • Patent number: 4150236
    Abstract: Tricyclic aromatic compounds of the formula ##STR1## including those wherein: (A) R.sub.1 is H, R.sub.2 is carbomethoxy, and R.sub.3 is methyl;(b) R.sub.1 is acetyl, R.sub.2 is carbomethoxy, and R.sub.3 is methyl;(c) R.sub.1 and R.sub.3 are methyl and R.sub.2 is carbomethoxy;(d) R.sub.1, R.sub.2, and R.sub.3 are hydrogen; and(e) R.sub.1 and R.sub.3 are methyl and R.sub.2 is hydrogenAre intermediates for the total synthesis of steroids.
    Type: Grant
    Filed: July 19, 1977
    Date of Patent: April 17, 1979
    Assignee: The United States of America as represented by the Department of Health, Education and Welfare
    Inventors: Ulrich Weiss, Kenner C. Rice
  • Patent number: 4148585
    Abstract: A laser Doppler velocimeter which can measure fluid flow in three dimensions, employing a laser beam projected through a rotating diffraction grating and spaced lenses, with a beam splitter in the major optical path between two lenses ahead of the flow channel through which the fluid passes. Selected pairs of laser-derived beams are directed through the fluid and intersect at a predetermined point in the fluid. The movement of the particles through interference patterns formed by the intersecting laser-derived beams generates further-modulated scattered light, which is focused on a photomultiplier tube, from the output of which a fluid velocity directional component signal is derived for each pair. There are four laser-divided beams, and different pairs of these beams can be selected, to provide measurements from which the components of the fluid velocity along three mutually orthogonal directions can be derived.
    Type: Grant
    Filed: February 11, 1977
    Date of Patent: April 10, 1979
    Assignee: The United States of America as represented by the Department of Health, Education & Welfare
    Inventors: C. Brent Bargeron, Owen J. Deters
  • Patent number: 4148888
    Abstract: 3-Deazaadenosine has been found to be an effective antiviral and antifocal agent in tissue culture of animals as evidenced by its activity against Rous sarcoma virus, influenza virus, vesicular stomatitis virus, Sindbis virus, and Newcastle disease virus in the range 0.03-0.3 mM. This compound has also shown use as an inhibitor of adenosylhomocysteine hydrolase from beef liver in the range of 0.001-0.008 mM (I.sub.50). The antiviral and antifocal effect is correlated with the inhibition of hydrolysis of adenosylhomocysteine in cells. This inhibition of adenosylhomocysteine hydrolase can also be demonstrated in livers of rats injected with 3-deazaadenosine.
    Type: Grant
    Filed: March 13, 1978
    Date of Patent: April 10, 1979
    Assignee: The United States of America as represented by the Department of Health, Education and Welfare
    Inventors: Giulio L. Cantoni, Peter K. Chiang, Henry H. Richards
  • Patent number: 4144237
    Abstract: Novel 3',4'-dehydro- and 4'-deoxo-vincristine and vinblastine compounds are obtained by coupling an indole unit of the catharanthine series and a dihydroindole unit of the vindoline series. Representative compounds of this series showed superior results when tested for activity against L1210 and P388 mouse leukemia.
    Type: Grant
    Filed: June 13, 1977
    Date of Patent: March 13, 1979
    Assignee: The United States of America as represented by the Department of Health, Education and Welfare
    Inventor: James P. Kutney
  • Patent number: 4140851
    Abstract: Certain trisubstituted pyrrolopyrimidine nucleosides are prepared from toyocamycin and have shown antitumor activity against L1210 and P388 murine leukemia. The particular compounds of interest are selected from the following structural formula: ##STR1## where X is haloY is halo; --NH.sub.2 ; --SH, --SR (where R is lower alkyl, benzyl); --OR (where OR is methoxy or alkoxy or where alk is C1-C6); amino (where the amino is --NH.sub.2, -alkyl amino or -dialkyl amino and alkyl is C1-C6); gamma gamma dimethyl allyl amino; benzyl amino; phenyl amino; selenoZ is CN; CXNH.sub.2 where X is .dbd.0, .dbd.S, or .dbd.Se, .dbd.NH, .dbd.NHNH.sub.2, .dbd.NOH. OR Z is = --CH.sub.2 NH.sub.2, --COR.dbd.NHRib.dbd..beta.-D-ribofuranosylPreferred members of this group of compounds are shown by the following structural formula: ##STR2## where X is ClY is Cl or NH.sub.2Z is CN, CONH.sub.2, or C.dbd.NOH--NH.sub.
    Type: Grant
    Filed: November 21, 1977
    Date of Patent: February 20, 1979
    Assignee: The United States of America as represented by the Department of Health, Education and Welfare
    Inventor: Leroy B. Townsend
  • Patent number: 4140761
    Abstract: Interferon introduced parenterally in a human host or stimulated by an inducer (PICLC) for a period of greater than 21 days results in a major decrease in all markers of infectivity, such as DNA polymerase, and such markers remain at a depressed level during the period of treatment. Where PICLC is utilized to induce interferon in the host, a serum level of 50 units per milliliter or higher is necessary for effective clinical treatment and 17 .times. 10.sup.4 - 6.0 .times. 10.sup.3 U/kg/day is an effective dose for exogenous interferon. Especially long-term treatment with exogenous interferon of greater than 21 days and up to 14 months results in clinical improvement for chronic hepatitis B virus (HBV) infection and this long-term treatment has resulted in sustained improvement even after cessation of treatment as well as resulting in a decrease in infectivity risk to others in close proximity to the infected human host. Such clinical improvement is marked by normalization of liver histology.
    Type: Grant
    Filed: April 11, 1977
    Date of Patent: February 20, 1979
    Assignee: The United States of America as represented by the Department of Health, Education & Welfare
    Inventors: John L. Gerin, Hilton B. Levy, Thomas C. Merigan, Robert H. Purcell, William S. Robinson
  • Patent number: 4136888
    Abstract: A tubular metal chair frame covered with canvas with a two-wheeled pivoted upwardly foldable front end and a pivoted rear support stand with two swivelled additional wheels, the support stand being lockable in a normal rearward position with the swivelled wheels engaging the floor and spaced rearwardly from the two front wheels. The support stand is foldable upwardly and can be locked in an elevated position, substantially coplanar with the upper portion of the frame. The lower portion of the frame is provided with a pair of parallel tread belts mounted on supports having rollers underlying the belts, the belts being located behind the front wheels and being usable to engage the edges of steps when the chair and its occupant are moved down stairs. Foldable handles are provided on the front end of the frame.
    Type: Grant
    Filed: October 7, 1977
    Date of Patent: January 30, 1979
    Assignee: The United States of America as represented by the Department of Health, Education and Welfare
    Inventors: William R. Bowie, Jr., George B. Sampson
  • Patent number: 4137248
    Abstract: The Pt compound may be prepared by reacting the known dichloro(1,2-diaminocyclohexane)platinum(II) (NSC 194814) with silver nitrate to replace chloro with nitro. Subsequently, benzene tricarboxylic acid is added to form an off-white precipitate (2 hrs, dark, 5.degree. C) of the desired product which is preferably utilized as the alkali metal salt.The 4-carboxyphthalato(1,2-diaminocyclohexane)-platinum(II) and alkali metal salts thereof may be combined in multiple drug regimen with substantially improved yield cures over the parent compound. For example, the compound denoted Pt-307 may be combined in a dual regimen with cyclophosphamide (CY) and in a triple drug regimen of Pt-307 plus cyclophosphamide (CY) and either 5-fluorouracil (5-FU) or hydroxyurea (HU) as the third component.
    Type: Grant
    Filed: August 29, 1977
    Date of Patent: January 30, 1979
    Assignee: The United States of America as represented by the Department of Health, Education and Welfare
    Inventors: Glen R. Gale, Paul Schwartz
  • Patent number: 4123944
    Abstract: A portable apparatus for measuring ultrasonic signal waves using interference between a reference reflected laser beam and one reflected from a gold-coated plastic film exposed to the sonic signal and located at the interface between liquids of different viscosity but which have substantially equal acoustic impedances. The liquids may respectively comprise water and fluorocarbon liquid.
    Type: Grant
    Filed: December 29, 1977
    Date of Patent: November 7, 1978
    Assignee: The United States of America as represented by the Department of Health, Education and Welfare
    Inventors: Reuben S. Mezrich, Cheston W. Robbins
  • Patent number: 4123524
    Abstract: The compound 6-amino-4-methyl-8-(.beta.-D-ribofuranosyl)pyrrolo[4,3,2-de]pyrimido[4,5-c ]pyridazines-5'-phosphate (a nucleotide) as a new compound and its method of synthesis by phosphorylation of the known 6-amino-4-methyl-8-(.beta.-D-ribofuranosyl)pyrrolo[4,3,2-de]pyrimido[4,5-c ]pyridazine (a nucleoside). The 5'-phosphate ester has utility against L-1210 mouse leukemia and has superior solubility over the parent compound which gives it a broader use pattern relative to dosage. This novel nucleotide also shows advantage in utilization as to pH over, for example, the hydrochloride salt which gives in solution a pH of 4 and is too acid for use.
    Type: Grant
    Filed: June 8, 1977
    Date of Patent: October 31, 1978
    Assignee: The United States of America as represented by the Department of Health, Education and Welfare
    Inventors: Leroy B. Townsend, Arthur F. Lewis, Linda W. Roti Roti
  • Patent number: 4115733
    Abstract: A readout device connected to a parent metering system contains a digital display for circumventing the non-linearity of analog meter movement in the parent system. The readout device displays both numerical and dimensional information in a clear, legible form with both probe and range scale factors accounted for in the display itself. A "probe" switch on the front panel of the module encodes the logarithm of the scale factor associated with the probe in use to a two's complement binary number, and the full scale range information from the "range" switch is encoded in the same manner. This information, along with function information from the "function" switch, is processed by a scale computation circuit which positions the decimal point and causes the units of measurement to be indicated accordingly.
    Type: Grant
    Filed: September 17, 1976
    Date of Patent: September 19, 1978
    Assignee: The United States of America as represented by of the Department of Health, Education and Welfare
    Inventor: Jeffrey L. Silberberg
  • Patent number: 4110461
    Abstract: A therapeutic method of alleviating the symptoms and relieving intraocular pressure associated with open or wide-angle glaucoma which comprises administering a compound selected from diphenylhydantoin (DPH), mephenytoin, and ethotoin in an amount ranging from 200-900 mg per day preferably on a split or divided dosage basis for a period of 2-5 months. A preferred regimen for DPH is 100 mg three times per day.
    Type: Grant
    Filed: March 19, 1973
    Date of Patent: August 29, 1978
    Assignee: The United States of America as represented by the Department of Health, Education and Welfare
    Inventors: Bernard Becker, Robert L. Stamper, Carl F. Asseff, Steven M. Podos
  • Patent number: 4108147
    Abstract: A direct contact microwave diathermy applicator consisting of a rectangular waveguide in which are secured two parallel Teflon dielectric loading slabs. This assembly is secured in a waveguide-coaxial cable adaptor, enabling the applicator to be energized from a microwave diathermy machine. The configuration of the applicator causes the tissue under treatment to exhibit approximately uniform heating patterns over a substantial portion of the treated tissue area and minimizes harmful scatter radiation. This uniform heating is particularly useful in effecting microwave induced hyperthermia treatment of cancer.
    Type: Grant
    Filed: November 1, 1976
    Date of Patent: August 22, 1978
    Assignee: The United States of America as represented by the Department of Health, Education and Welfare
    Inventor: Gideon Kantor
  • Patent number: 4106493
    Abstract: A caloric testing apparatus for introducing heated or cooled air, under direct visual control, into the outer ear canal of a human subject for purposes of testing inner ear balance mechanisms. The device includes a speculum for observing the ear canal during the flow of air, thereby assuring proper direction of the impinging air jet. The apparatus includes temperature-controlled liquid baths for providing hot or cold air, and has arrangements for providing suitably timed irrigation periods, adjustable so as to control the magnitudes of the caloric stimulations. Measurements can be made by the electrical recording of eye movements for accurate measurement of nystagmic response intensity.
    Type: Grant
    Filed: January 13, 1977
    Date of Patent: August 15, 1978
    Assignee: The United States of America as represented by the Department of Health, Education and Welfare
    Inventors: Leonard R. Proctor, Raymond G. Byrnes